During the recent Maharashtra assembly session, questions were raised about the rising tuberculosis cases. The current treatment options available to us in India are limited; many come with severe side effects like severe peripheral neuropathy, pink to black brown discoloration of skin lasting up to three years, and potentially even psychosis, making it an extremely difficult, and at times hopeless …
Mumbai: There’s some cheer in store for drug-resistant tuberculosis patients, who have been abiding a prolonged treatment regimen with severe side-effects. HT Image The present treatment guideline, which has 13 to 14 drugs given daily for a period of 18 to 24 months, was formulated two and a half years ago. The core committee of the National TB Elimination Programme …
NEW DELHI: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of Pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. “We welcome this news and commend Viatris, MedAccess, and TB Alliance for the announcement of a new agreement to reduce the price of pretomanid, a drug used to treat …
Discarding concerns of efficacy with a lower dose, a three-drugs-based new treatment regimen has a higher success rate than the existing drug-resistant TB treatment, says the latest ZeNix study published in the New England Journal of Medicine. The “bedaquiline-pretomanid-linezolid” regimen, abbreviated as the BPaL regimen, has been reported to have around 90% efficacy against highly drug-resistant tuberculosis, but the incidence …
